Rhenium Re186 obisbemeda

REYOBIQ
DEVELOPMENT STEP phase-2
SPONSOR MATRIX Plus Therapeutics [PSTV]
MECHANISM TARGET // UNMAPPED_TARGET

[THERAPEUTIC_PROFILE]

Target Indications

Recurrent Glioblastoma, Pediatric Brain Cancer, Leptomeningeal Metastases

Mechanism Abstract

REYOBIQ™ (rhenium Re186 obisbemeda): a Rhenium-186 radiolabeled therapeutic targeting recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

[CLINICAL_TRIALS_REGISTRY]

// NO_ACTIVE_REGISTRY_STUDIES_FOUND (Rhenium Re186 obisbemeda)